Moleculin partners with CIC biomaGUNE for preclinical Annamycin glioblastoma study

Moleculin Biotech, Inc.

Agreement supplies Annamycin for investigator-initiated preclinical research at CIC biomaGUNE, Spain.
Studies compare intra-arterial L-Annamycin and Free-Annamycin vs Doxil and free doxorubicin in mouse GBM models.
Principal investigator Jesús Ruiz-Cabello to lead the evaluation of tumor progression.
Annamycin holds FDA Fast Track and Orphan Drug Designation for AML and STS lung metastases.
GBM is the most common malignant brain tumor with median survival of 15 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.